tiprankstipranks
Trending News
More News >
Pharvaris price target raised to $27 from $25 at Wedbush
PremiumThe FlyPharvaris price target raised to $27 from $25 at Wedbush
23d ago
Pharvaris price target lowered to $25 from $28 at Cantor Fitzgerald
Premium
The Fly
Pharvaris price target lowered to $25 from $28 at Cantor Fitzgerald
23d ago
Pharvaris: Strong Buy Rating Backed by Regulatory Success and Promising Clinical Progress
Premium
Ratings
Pharvaris: Strong Buy Rating Backed by Regulatory Success and Promising Clinical Progress
24d ago
Pharvaris: Buy Rating Backed by Clinical Progress, Market Potential, and Strong Financial Position
PremiumRatingsPharvaris: Buy Rating Backed by Clinical Progress, Market Potential, and Strong Financial Position
2M ago
Pharvaris Faces Uncertainty Amid Competitive HAE Market and Pivotal Trial Challenges
Premium
Ratings
Pharvaris Faces Uncertainty Amid Competitive HAE Market and Pivotal Trial Challenges
2M ago
Pharvaris’s Strategic Advancements and Strong Financial Position Drive Buy Rating
Premium
Ratings
Pharvaris’s Strategic Advancements and Strong Financial Position Drive Buy Rating
2M ago
Pharvaris reports Q4 EPS (EUR 0.64) vs. (EUR 0.95) last year
PremiumThe FlyPharvaris reports Q4 EPS (EUR 0.64) vs. (EUR 0.95) last year
2M ago
Pharvaris says EC grants orphan designation to deucrictibant
Premium
The Fly
Pharvaris says EC grants orphan designation to deucrictibant
2M ago
Pharvaris reports safety and efficacy data of deucrictibant
Premium
The Fly
Pharvaris reports safety and efficacy data of deucrictibant
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100